4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara, Rosandra N Kaplan, George H Patterson, Terry J Fry, Rimas J Orentas, Crystal L Mackall, Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara, Rosandra N Kaplan, George H Patterson, Terry J Fry, Rimas J Orentas, Crystal L Mackall
Abstract
Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens. It remains unknown whether the impressive effects of CD19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior functionality of the CD19 CAR itself. We show that tonic CAR CD3-ζ phosphorylation, triggered by antigen-independent clustering of CAR single-chain variable fragments, can induce early exhaustion of CAR T cells that limits antitumor efficacy. Such activation is present to varying degrees in all CARs studied, except the highly effective CD19 CAR. We further determine that CD28 costimulation augments, whereas 4-1BB costimulation reduces, exhaustion induced by persistent CAR signaling. Our results provide biological explanations for the antitumor effects of CD19 CARs and for the observations that CD19 CAR T cells incorporating the 4-1BB costimulatory domain are more persistent than those incorporating CD28 in clinical trials.
Figures
References
- Lee DW, et al. The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer. Clinical Cancer Research. 2012;18(10):2780–2790.
- Sadelain M, Brentjens R, Rivière I. The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discovery. 2013;3(4):388–398.
- Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet. 2014
- Maude SL, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine. 2014;371(16):1507–1517.
- Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–2720.
- Porter DL, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine. 2011;365(8):725–733.
- Grupp SA, et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine. 2013;368(16):1509–1518.
- Savoldo B, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of Clinical Investigation. 2011;121(5):1822–1826.
- Brentjens RJ, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Science Translational Medicine. 2013;5(177):177ra138–177ra138.
- Davila ML, et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine. 2014;6(224) 224ra225.
- Kershaw MH, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research. 2006;12(20):6106–6115.
- Park JR, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular therapy. 2007;15(4):825–833.
- Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature medicine. 2008;14(11):1264–1270.
- Louis CU, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050–6056.
- Till BG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940–3950.
- Lamers CHJ, et al. Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity. Mol Ther. 2013;21(4):904–912.
- Robbins PF, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. The Journal of Immunology. 2004;173(12):7125–7130.
- Kowolik CM, et al. CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Research. 2006;66(22):10995–11004.
- Milone MC, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy. 2009;17(8):1453–1464.
- Haso W, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165–1174.
- Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–1544.
- Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of experimental medicine. 2010;207(10):2187–2194.
- Baitsch L, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. The Journal of clinical investigation. 2011;121(6):2350.
- Zhou Q, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–4510.
- Woo S-R, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer research. 2012;72(4):917–927.
- Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine. 2012;366(26):2443–2454.
- Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138(1):30–50.
- Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499.
- Rossig C, et al. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. International journal of cancer. 2001;94(2):228–236.
- Pulè MA, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy. 2005;12(5):933–941.
- Hudecek M, et al. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer immunology research. 2014 canimm. 0127.2014.
- Kochenderfer JN, et al. Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. Journal of immunotherapy (Hagerstown, Md: 1997) 2009;32(7):689.
- Shin H, et al. A Role for the Transcriptional Repressor Blimp-1 in CD8+ T Cell Exhaustion during Chronic Viral Infection. Immunity. 2009;31(2):309–320.
- Doering TA, et al. Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8< sup>+</sup> T Cell Exhaustion versus Memory. Immunity. 2012;37(6):1130–1144.
- Paley MA, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338(6111):1220–1225.
- Friend LD, et al. A dose-dependent requirement for the proline motif of CD28 in cellular and humoral immunity revealed by a targeted knockin mutant. The Journal of experimental medicine. 2006;203(9):2121–2133.
- Dodson LF, et al. Targeted knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation. Molecular and cellular biology. 2009;29(13):3710–3721.
- Zhao Y, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. The Journal of Immunology. 2009;183(9):5563–5574.
- Nieba L, Honegger A, Krebber C, Plückthun A. Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Engineering. 1997;10(4):435–444.
- Dolezal O, et al. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the VL domain of the scFv-0 (VL− VH) molecule is primarily responsible for formation of a tetramer-trimer equilibrium. Protein engineering. 2003;16(1):47–56.
- Whitlow M, et al. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Engineering. 1994;7(8):1017–1026.
- Wherry EJ, et al. Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection. Immunity. 2007;27(4):670–684.
- Crawford A, et al. Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection. Immunity. 40(2):289–302.
- Guest RD, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. Journal of Immunotherapy. 2005;28(3):203.
- James SE, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. The Journal of Immunology. 2008;180(10):7028–7038.
- Frigault MJ, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer immunology research. (in the press)
- Agnellini P, et al. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proceedings of the National Academy of Sciences. 2007;104(11):4565–4570.
- Vezys V, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. The Journal of Immunology. 2011;187(4):1634–1642.
- Wang C, et al. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. The Journal of Immunology. 2007;179(12):8252–8263.
- Porter D, et al. Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. Blood. 2013;122(21):4162–4162.
- Doedens AL, et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nat Immunol. 2013;14(11):1173–1182.
- Pearce EL, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460(7251):103–107.
- van der Windt Gerritje JW, et al. Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development. Immunity. 2012;36(1):68–78.
- Araki K, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108–112.
- Roederer M, Nozzi JL, Nason MC. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry Part A. 2011;79(2):167–174.
- Morgan RA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human gene therapy. 2012;23(10):1043–1053.
- Brochet X, Lefranc M-P, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Research. 2008;36(suppl 2):W503–W508.
- Sen G, et al. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. Journal of Immunotherapy. 1998;21(1):75–83.
- Jena B, et al. Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials. PLoS ONE. 2013;8(3):e57838.
- Edelstein A, et al. Computer control of microscopes using µManager. Current protocols in molecular biology. 2010 14.20. 11-14.20. 17.
- Elangovan M, et al. Characterization of one-and two-photon excitation fluorescence resonance energy transfer microscopy. Methods. 2003;29(1):58–73.
- Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nature methods. 2012;9(7):676–682.
- Olenych SG, Claxton NS, Ottenberg GK, Davidson MW. The fluorescent protein color palette. Current Protocols in Cell Biology. 2007
- Martin CE, et al. IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood. 2013;121(22):4484–4492.
Source: PubMed